
While Antibody-Drug Conjugates (ADCs) offer promising treatment options for metastatic HER2-low breast cancer, the optimal sequencing of these agents remains unclear due to limited data on resistance mechanisms and the efficacy of subsequent treatments.


coremsg

Kathy D. Miller, MD, and Stephanie L. Graff, MD, discuss sequencing of ADCs for metastatic HER2-low breast cancer including sequencing, toxicities, and clinical trials.

Episode 5: Sequencing of ADCs for Metastatic HER2-Low Disease

sequencing-antibody-drug-conjugates-adcs-for-metastatic-her2-low-breast-cancer-a-complex-decision-making-process


Sequencing Antibody-Drug Conjugates (ADCs) for Metastatic HER2-Low Breast Cancer: A Complex Decision-Making Process
